ArticleJournal of virology1992
Comparative analysis of Rev function in human immunodeficiency virus types 1 and 2.
Article in Journal of virology, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Co-Infections and Superinfections between HIV-1 and Other Human Viruses at the Cellular Level.Pathogens (Basel, Switzerland) · 2024Review
- HIV-2 inhibits HIV-1 gene expression via two independent mechanisms during cellular co-infection.Journal of virology · 2023Article
- Human Retrovirus Genomic RNA Packaging.Viruses · 2022Review
- The HIV-2 Rev-response element: determining secondary structure and defining folding intermediates.Nucleic acids research · 2013Article
- Nonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: a possible role for the p2 domain of Gag in RNA encapsidation.Journal of virology · 1998Article
- Nuclear transport of human immunodeficiency virus type 1, visna virus, and equine infectious anemia virus Rev proteins: identification of a family of transferable nuclear export signals.Journal of virology · 1996Article
- A potentially novel approach for the gene therapy of HIV-1 disease.Journal of molecular medicine (Berlin, Germany) · 1995Review
- Inhibition of HIV-1 expression by HIV-2.Journal of molecular medicine (Berlin, Germany) · 1995Article
- Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual.Journal of virology · 1995Article
- Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes.Journal of virology · 1995Article
- Identification of the activation domain of equine infectious anemia virus rev.Journal of virology · 1993Article
- Transcomplementation of simian immunodeficiency virus Rev with human T-cell leukemia virus type I Rex.Journal of virology · 1993Article
- Mechanism of action of regulatory proteins encoded by complex retroviruses.Microbiological reviews · 1992Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The Rev proteins of the related but distinct human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) display incomplete functional reciprocity. One possible explanation for this observation is that HIV-2 Rev is unable to interact with the HIV-1 Rev-response element (RRE1). However, an analysis of the biological activity of chimeric proteins derived from HIV-1 and HIV-2 Rev reveals that this target specificity does not map to the Rev RNA binding domain but is instead primarily determined by sequences known to mediate Rev multimerization. Both HIV-1 and HIV-2 Rev are shown to bind the RRE1 in vitro with identical RNA sequence specificity. The observation that HIV-2 Rev can inhibit RRE1-dependent HIV-1 Rev function in trans indicates that the direct interaction of HIV-2 Rev with the RRE1 also occurs in vivo. These data suggest that HIV-2 Rev forms a protein-RNA complex with the RRE1 that leads to only minimal Rev activity. It is hypothesized that this low level of Rev function results from the incomplete and/or aberrant multimerization of HIV-2 Rev on this heterologous RNA target sequence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.